SAMHD1 acetylation enhances its deoxynucleotide triphosphohydrolase activity and promotes cancer cell proliferation
Metrics: PDF 1331 views | HTML 3283 views | ?
Eun Ji Lee1, Ji Hae Seo2, Ji-Hyeon Park1, Tam Thuy Lu Vo1, Sunho An1, Sung-Jin Bae1, Hoang Le1, Hye Shin Lee1, Hee-Jun Wee1, Danbi Lee3, Young-Hwa Chung3, Jeong A. Kim4, Myoung-Kuk Jang5, Soo Hyung Ryu6, Ensil Yu7, Se Hwan Jang8, Zee Yong Park8 and Kyu-Won Kim1,9
1SNU-Harvard NeuroVascular Protection Research Center, College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 08826, Korea
2Department of Biochemistry, Keimyung University School of Medicine, Daegu 42601, Korea
3Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul 05505, Korea
4DNA Link Inc., Seoul 03759, Korea
5Department of Internal Medicine, Hallym University College of Medicine, Kangdong Sacred Heart Hospital, Seoul 05355, Korea
6Department of Internal Medicine, Inje University College of Medicine, Seoul Paik Hospital, Seoul 04551, Korea
7Department of Pathology, University of Ulsan College of Medicine, Asan Medical Center, Seoul 05505, Korea
8School of Life Sciences, Gwangju Institute of Science & Technology, Gwangju 61005, Korea
9Crop Biotechnology Institute, GreenBio Science and Technology, Seoul National University, Pyeongchang 25354, Korea
Kyu-Won Kim, email: [email protected]
Keywords: SAMHD1, acetylation, dNTPase, cell cycle, cancer
Received: April 19, 2017 Accepted: June 28, 2017 Published: July 31, 2017
SAM domain and HD domain containing protein 1 (SAMHD1) is a deoxynucleotide triphosphohydrolase (dNTPase) that inhibits retroviruses by depleting intracellular deoxynucleotide triphosphates (dNTPs) in non-cycling myeloid cells. Although SAMHD1 is expressed ubiquitously throughout the human body, the molecular mechanisms regulating its enzymatic activity and function in non-immune cells are relatively unexplored. Here, we demonstrate that the dNTPase activity of SAMHD1 is regulated by acetylation, which promotes cell cycle progression in cancer cells. SAMHD1 is acetylated at residue lysine 405 (K405) in vitro and in vivo by an acetylatransferase, arrest defective protein 1 (ARD1). Acetylated SAMHD1 wildtype proteins have enhanced dNTPase activity in vitro, whereas non-acetylated arginine substituted mutants (K405R) do not. K405R mutant expressing cancer cells have reduced G1/S transition and slower proliferation compared to wildtype. SAMHD1 acetylation levels are strongest during the G1 phase, indicating a role during G1 phase. Collectively, these findings suggest that SAMHD1 acetylation enhances its dNTPase activity and promotes cancer cell proliferation. Therefore, SAMHD1 acetylation may be a potent therapeutic target for cancer treatment.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.